Acknowledgements We thank the participants in this study
For patients considering GLP-1 therapy alongside rheumatoid arthritis management, precision assessment matters
[17] IQVIA Institute for Human Data Science
Lilly is also running two other trials with eloralintide plus tirzepatide, including another mid-stage study in obese and overweight type 2 diabetes patients, with an initial completion date in June 2026, and a Phase I trial in nondiabetic individuals, scheduled to complete in October 2025
If you notice redness, swelling, or tenderness at a site, skip that area for at least two weeks and switch to a different region
Three myths the microinfusion category needs to retire Myth 01 "All peptides are the same." They are not